GRI Bio (GRI) Total Current Liabilities (2020 - 2026)
GRI Bio (GRI) posted quarterly Total Current Liabilities of $794000.0 for Q1 2026, down 71.43% year-over-year from $2.8 million in Q1 2025, and down 69.96% quarter-over-quarter from $2.6 million in Q4 2025.
GRI Bio (GRI) Total Current Liabilities (2020 - 2026) Analysis & Trends
GRI Bio's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $794000.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 71.43% year-over-year to $794000.0; the TTM figure through Mar 2026 stood at $794000.0 (down 71.43% YoY), while the FY2025 annual figure was $2.6 million, up 61.55% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $794000.0, down from $2.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $4.3 million in Q2 2022, with the low at $794000.0 in Q1 2026.
- The 5-year median for Total Current Liabilities is $2.2 million (2023), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 158.65% in 2022, then tumbled 71.43% in 2026.
- GRI Bio's Total Current Liabilities stood at $2.0 million in 2022, then surged by 35.26% to $2.7 million in 2023, then tumbled by 39.34% to $1.6 million in 2024, then jumped by 61.55% to $2.6 million in 2025, then slumped by 69.96% to $794000.0 in 2026.
- Business Quant data shows GRI's Total Current Liabilities at $794000.0 in Q1 2026, $2.6 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 794,000.00 |
| Dec 31, 2025 | 2.64 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Mar 31, 2021 | 2.43 Mn |